GR3023717T3 - Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv. - Google Patents

Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv.

Info

Publication number: GR3023717T3
Authority: GR; Greece
Prior art keywords: protein; pct; native; hiv; membrane proteins
Prior art date: 1993-01-16

Application number

GR970401358T

Other languages

English (en)

Inventor

Manfred Schawaller

Original Assignee

Manfred Schawaller

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-16

Filing date

1997-06-10

Publication date

1997-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6478309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3023717(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-10 Application filed by Manfred Schawaller filed Critical Manfred Schawaller

1997-09-30 Publication of GR3023717T3 publication Critical patent/GR3023717T3/el

Links

229960005486 vaccine Drugs 0.000 title abstract 3
108010065667 Viral Matrix Proteins Proteins 0.000 title abstract 2
241000725303 Human immunodeficiency virus Species 0.000 abstract 3
108020001580 protein domains Proteins 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
208000030507 AIDS Diseases 0.000 abstract 2
108090000790 Enzymes Proteins 0.000 abstract 2
102000004190 Enzymes Human genes 0.000 abstract 2
108010052285 Membrane Proteins Proteins 0.000 abstract 1
102000018697 Membrane Proteins Human genes 0.000 abstract 1
230000029087 digestion Effects 0.000 abstract 1
231100000676 disease causative agent Toxicity 0.000 abstract 1
108010078428 env Gene Products Proteins 0.000 abstract 1
210000003527 eukaryotic cell Anatomy 0.000 abstract 1
239000000178 monomer Substances 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

GR970401358T 1993-01-16 1997-06-10 Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv. GR3023717T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4301017		1993-01-16
PCT/DE1994/000022 WO1994016081A1 (de)	1993-01-16	1994-01-12	Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv

Publications (1)

Publication Number	Publication Date
GR3023717T3 true GR3023717T3 (en)	1997-09-30

Family

ID=6478309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GR970401358T GR3023717T3 (en)	1993-01-16	1997-06-10	Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv.

Country Status (9)

Country	Link
US (1)	US6140059A (el)
EP (1)	EP0679187B2 (el)
JP (1)	JP3658690B2 (el)
AT (1)	ATE153380T1 (el)
DE (2)	DE4400659C2 (el)
DK (1)	DK0679187T4 (el)
ES (1)	ES2102815T5 (el)
GR (1)	GR3023717T3 (el)
WO (1)	WO1994016081A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2781676B1 (fr) *	1998-07-31	2004-04-02	Pasteur Merieux Serums Vacc	Trimere du produit d'expression du gene env de hiv
AU2221600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) *	1998-12-31	2000-07-31	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP4776075B2 (ja)	1998-12-31	2011-09-21	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	改変ｈｉｖｅｎｖポリペプチド
US7935805B1 (en) *	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1214333A4 (en) *	1999-09-17	2005-01-19	Dana Farber Cancer Inst Inc	SOLUBLE STABILIZED GLYCOPROTEIN TRIMERS
US7179468B1 (en)	2000-06-08	2007-02-20	Cornell Research Foundation, Inc.	Antigen for developing neutralizing antibodies to human immunodeficiency virus
EP1411770A4 (en) *	2001-07-05	2006-05-10	Chiron Corp	POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
EP2280074A3 (en) *	2001-07-05	2011-06-22	Novartis Vaccines and Diagnostics, Inc.	Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) *	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) *	2001-08-31	2013-04-30	Chiron Corporation	Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
WO2004101598A2 (en) *	2003-05-09	2004-11-25	Research Development Foundation	Insertion of furin protease cleavage sites in membrane proteins and uses thereof
US7358334B1 (en)	2003-11-14	2008-04-15	Jay W Chaplin	B cell-targeted toxins for humoral immune response reduction and methods of use thereof
US9216212B2 (en)	2005-08-05	2015-12-22	University Of Massachusetts	Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) *	2005-08-05	2011-05-31	University Of Massachusetts	Virus-like particles as vaccines for paramyxovirus
US8580270B2 (en)	2008-09-30	2013-11-12	University Of Massachusetts	Respiratory synctial virus (RSV) sequences for protein expression and vaccines
AU2010222942B2 (en)	2009-03-10	2013-01-10	Baylor Research Institute	Anti-CD40 antibodies and uses thereof
CN102770457A (zh) *	2009-03-10	2012-11-07	贝勒研究院	靶向抗原呈递细胞的疫苗
DK2406289T3 (en) *	2009-03-10	2017-05-01	Baylor Res Inst	ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
AU2011230619C1 (en)	2010-03-25	2016-06-23	Oregon Health & Science University	CMV glycoproteins and recombinant vectors
CA2831294A1 (en)	2011-03-25	2012-10-04	Baylor Research Institute	Compositions and methods to immunize against hepatitis c virus
HUE037408T2 (hu)	2011-06-10	2018-08-28	Univ Oregon Health & Science	CMV glikoproteinek és rekombináns vektorok
US9402894B2 (en)	2011-10-27	2016-08-02	International Aids Vaccine Initiative	Viral particles derived from an enveloped virus
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Methods of identifying novel HIV-1 immunogens
US10058604B2 (en)	2013-10-07	2018-08-28	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
CN120939216A (zh)	2014-01-13	2025-11-14	贝勒研究院	抗hpv和hpv相关的疾病的新疫苗
EP3069730A3 (en)	2015-03-20	2017-03-15	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en)	2015-03-23	2018-04-03	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US10610585B2 (en)	2017-09-26	2020-04-07	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and compositions for treating and preventing HIV

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3731874A1 (de) *	1987-09-18	1989-03-30	Schering Ag	Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen
IL89567A0 (en) *	1988-03-28	1989-09-10	Univ Leland Stanford Junior	Mutated hiv envelope protein
CA2077753C (en) †	1990-03-09	2000-02-29	Nancy L. Haigwood	Purified gp120 composition retaining natural conformation
FR2676071B1 (fr) *	1991-05-02	1994-11-18	Transgene Sa	Nouveau variant gp160 non-clivable, soluble, de forme hybride.

1994
- 1994-01-12 WO PCT/DE1994/000022 patent/WO1994016081A1/de not_active Ceased
- 1994-01-12 US US08/448,619 patent/US6140059A/en not_active Expired - Fee Related
- 1994-01-12 ES ES94904568T patent/ES2102815T5/es not_active Expired - Lifetime
- 1994-01-12 EP EP94904568A patent/EP0679187B2/de not_active Expired - Lifetime
- 1994-01-12 DK DK94904568T patent/DK0679187T4/da active
- 1994-01-12 AT AT94904568T patent/ATE153380T1/de not_active IP Right Cessation
- 1994-01-12 DE DE4400659A patent/DE4400659C2/de not_active Expired - Fee Related
- 1994-01-12 JP JP51558794A patent/JP3658690B2/ja not_active Expired - Fee Related
- 1994-01-12 DE DE59402827T patent/DE59402827D1/de not_active Expired - Fee Related
1997
- 1997-06-10 GR GR970401358T patent/GR3023717T3/el unknown

Also Published As

Publication number	Publication date
DE59402827D1 (de)	1997-06-26
WO1994016081A1 (de)	1994-07-21
DE4400659C2 (de)	1995-07-27
JPH08505769A (ja)	1996-06-25
ES2102815T3 (es)	1997-08-01
DK0679187T4 (da)	2001-09-17
EP0679187B2 (de)	2001-07-04
DK0679187T3 (da)	1997-12-08
DE4400659A1 (de)	1994-07-21
ATE153380T1 (de)	1997-06-15
US6140059A (en)	2000-10-31
ES2102815T5 (es)	2001-11-16
EP0679187B1 (de)	1997-05-21
JP3658690B2 (ja)	2005-06-08
EP0679187A1 (de)	1995-11-02

Publication	Publication Date	Title
GR3023717T3 (en)	1997-09-30	Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv.
EP0280710A4 (en)	1989-03-14	DNA ENCODING THE T CELL SURFACE PROTEIN T4 AND USE OF T4 FRAGMENTS IN THE TREATMENT OF AIDS.
US6420141B1 (en)	2002-07-16	Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids
DE3588254D1 (de)	2007-10-25	Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
WO2021000968A3 (zh)	2021-02-18	一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
AU3762889A (en)	1990-01-05	Hiv-3 retrovirus and its use
ES2010727A6 (es)	1989-12-01	Metodo para producir lineas celulares que producen anticuerpos monoclonales reactivos frente a determinantes antigenicos de gp110 o de p25 de hiv.
WO1991009872A3 (en)	1992-04-02	Hiv-1 env fragment fusion protein
JP2002533125A5 (el)	2007-02-22
Weiss et al.	1992	Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA
EP0272858A3 (en)	1989-07-12	Recombinant hiv envelope proteins produced in insect cells
AU1463097A (en)	1997-08-01	Helicobacter pylori bacterioferritin
ES2010231A6 (es)	1989-11-01	Metodo para fabricar particulas de proteinas de fusion y metodo para expresar estas proteinas.
JP2004509601A5 (el)	2004-12-24
US5354683A (en)	1994-10-11	Human immunodeficiency virus specific proteolytic enzyme and a method for its synthesis and renaturation
EP1421951A3 (en)	2005-10-05	Conserved motif of hepatitis C virus E2/NS1 region
JP3453611B2 (ja)	2003-10-06	ハイブリッド形態の新規可溶性、非開裂性ｇｐ１６０変異体
AUPM772494A0 (en)	1994-09-22	Improvements in production of proteins in host cells
IL158981A0 (en)	2004-05-12	Tsg101 as inhibitor of hiv production
DE69021886D1 (de)	1995-09-28	Äusseres membranprotein p1 und peptide von haemophilus influenzae typ b.
Barnes	1986	Strategies for an AIDS Vaccine: In their attempts to develop a vaccine against AIDS, many scientists focus on raising antibodies to a protein from the AIDS virus, a strategy that some researchers think may require modification
ATE369427T1 (de)	2007-08-15	Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine
BE1000167A4 (fr)	1988-07-05	Antigene du virus de l'hepatite b et procede pour sa production.
NZ507942A (en)	2003-06-30	Viral chimeras comprised of CAEV and HIV-1 genetic elements
AP2005A (en)	2009-06-10	Process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof.